Tirzepatide

Tirzepatide

20mg / Vial
£70.00
£70.00
Skip to product information
Tirzepatide
  • Tirzepatide
  • Tirzepatide
Tirzepatide

Tirzepatide

£70.00
£70.00
Size
Type
For Research Purposes Only — Not For Human Use This product is intended solely for laboratory and in-vitro research. Not for human consumption, medical use, or self-administration.
Third-party tested
1–2 day tracked dispatch
Discreet packaging
99%+ purity guaranteed
For Research Use OnlyThis compound is strictly for laboratory and in-vitro research. Not for human consumption or medical use.
Reconstitution
Pen format? Pens are supplied pre-mixed and ready for research use — no reconstitution required. The steps below apply to lyophilized vials only.
  1. Swab both vial stoppers with alcohol and allow to dry.
  2. Draw the required volume of bacteriostatic water with a sterile syringe.
  3. Add the water slowly down the inside wall of the vial — never directly onto the powder.
  4. Swirl gently until fully dissolved. Never shake.
  5. Confirm the solution is clear and particle-free.
  6. Label with date and concentration, then refrigerate at 2–8 °C.
Full guide & dose calculator
Storage & Handling
  • Lyophilized vials: refrigerate sealed at 2–8 °C away from light; freeze at −20 °C for storage beyond 6 months.
  • After reconstitution: refrigerate at 2–8 °C; typically stable 4–8 weeks with bacteriostatic water. Do not freeze once mixed.
  • Pre-mixed pens: arrive ready to use — refrigerate at 2–8 °C with the cap on and never freeze.
  • General: avoid direct sunlight, heat and repeated temperature swings; minimise agitation.
Quality & Shipping FAQ
  • Is this compound tested? Yes — every batch is third-party tested by accredited labs (HPLC & mass spectrometry) at 99%+ verified purity.
  • How is it supplied? As lyophilized powder in a sealed sterile vial (or pre-mixed pen where offered), with research-use labelling.
  • How fast is dispatch? 1–2 working day dispatch, 2–3 days UK delivery, in plain discreet packaging.
  • What is it for? Strictly laboratory and in-vitro research — not for human or veterinary consumption, medical use or self-administration.
View the peer-reviewed research
Packaging update Our branded boxes are temporarily out of stock. Until new stock lands, orders ship in plain, discreet packaging — the same product inside, sealed and dispatched with the same care. Thank you for your patience.

Tirzepatide

Tirzepatide is a synthetic peptide studied in metabolic research as a dual agonist of the GIP and GLP-1 receptors.

About the compound

Tirzepatide is investigated in laboratory and clinical research for its simultaneous interaction with two receptors involved in metabolic signalling: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual-receptor activity makes it a widely referenced compound in metabolic research.

Specifications

  • Purity: 99%+ (third-party verified)
  • Independently tested before dispatch
  • Presented as lyophilised (freeze-dried) powder
  • Supplied for in-vitro laboratory research only

FAQ

Is it tested? Yes — every batch is independently tested to 99%+ purity before dispatch.
What form does it arrive in? Lyophilised powder.
What is this sold for? Laboratory and research use only. Not for human or animal consumption.

⚖ For Laboratory Research Use Only — Not for Human Consumption.
Peer-Reviewed Evidence

Research & Studies

Independent published research on Tirzepatide

Tirzepatide Metabolic Research Human Phase 3

Tirzepatide: Dual GIP/GLP-1 Agonism and Up to 20.9% Weight Reduction — SURMOUNT-1

New England Journal of Medicine · Jastreboff et al., 2022

Tirzepatide is a unimolecular dual agonist targeting both GIP and GLP-1 receptors. The SURMOUNT-1 Phase 3 trial demonstrated mean weight reductions of up to 20.9% from baseline at the 15mg dose. Research revealed that simultaneous activation of both receptor pathways produces synergistic metabolic effects — significantly greater reductions in fasting insulin, triglycerides, and waist circumference compared with selective GLP-1 agonism alone.

Dual Agonist SURMOUNT-1 GIP/GLP-1
Tirzepatide Metabolic Research Human Phase 3

Tirzepatide vs Semaglutide: Superior Glycaemic Control and Weight Reduction — SURPASS-2

New England Journal of Medicine · Frías et al., 2021

The SURPASS-2 trial enrolled 1,879 adults with type 2 diabetes comparing tirzepatide directly against semaglutide. All three tirzepatide doses produced greater reductions in HbA1c (up to −2.07% vs −1.86%) and body weight (up to −11.2 kg vs −5.7 kg). The 15mg arm achieved HbA1c below 5.7% in 27% of participants. Results established tirzepatide's superiority over the leading GLP-1 monotherapy for both metabolic control and fat reduction.

Human RCT SURPASS-2 HbA1c Reduction
Tirzepatide Metabolic Research Human Phase 3

Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

New England Journal of Medicine · Jastreboff et al., 2022

A phase 3, double-blind, randomised controlled trial of 2,539 adults with obesity assigned to once-weekly tirzepatide (a dual GIP/GLP-1 receptor agonist) or placebo for 72 weeks. Mean weight reduction reached 20.9% at the 15 mg dose versus 3.1% with placebo, and roughly 9 in 10 participants on tirzepatide lost weight. The trial established dual-incretin agonism as a benchmark for pharmacological weight management.

Dual GIP/GLP-1 Phase 3 RCT 72 Weeks
View the full research library →

You may also like